Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of SciClone Pharmaceuticals Inc.

New York, NY (GLOBE NEWSWIRE) - Pomerantz Haudek Grossman & Gross LLP is investigating claims on behalf of investors of SciClone Pharmaceuticals Inc. ("SciClone" or the "Company") (Nasdaq:SCLN) to determine whether it has violated federal securities laws by issuing false and misleading statements to its shareholders. Investors are advised to contact Nicola Brown at 888-476-6529 or email info@pomlaw.com.

SciClone is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases such as cancer, hepatitis B, hepatitis C, cystic fibrosis and immune system disorders. The Pomerantz Firm's investigation centers on the August 9, 2010 disclosures that SciClone was advised by the Securities & Exchange Commission that it has initiated a formal, non-public investigation of SciClone. In connection with the investigation, the SEC issued a subpoena requesting documents concerning certain business dealings in China. The Company further revealed that the U.S. Department of Justice is investigating whether the Company has complied with the Foreign Corrupt Practices Act. As a result of these revelations, SciClone securities declined more than 29% or $1.03 on August 10, 2010.

The Pomerantz Firm, with offices in New York, Chicago, Washington, D.C., Columbus, Ohio and Burlingame, California, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz Haudek Grossman & Gross LLP

© Copyright 2010, GlobeNewswire, Inc. All Rights Reserved.